Search Press releases Keywords From To 14 Nov 2024 New BIMZELX[®] (bimekizumab-bkzx) data at ACR Convergence 2024 highlights UCB’s efforts to deliver differentiated care for patients with psoriatic arthritis and axial spondyloarthritis Read More 12 Nov 2024 Transparency notification BlackRock, Inc. Read More 8 Nov 2024 Transparency notification BlackRock, Inc. Read More 5 Nov 2024 UCB completes sale of established brands and updates 2024 financial guidance Read More 31 Oct 2024 UCB Presents Encouraging Data on Bepranemab in Early Alzheimer’s Disease in Phase 2a Study at CTAD 2024 Read More 22 Oct 2024 UCB Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting Read More Pagination First page Previous page Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 2 of 74 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe